ASGR1 and liver cancer: The preparation of galactosyl or N-acetylgalactosaminyl-modified drug delivery systems, by recognizing ASGPR specifically and increasing the drug concentration in liver cells, can facilitate active targeting to the liver, and consequently, it has gradually become a new treatment option for liver cancer (Cheng et al., 2012; Wang et al., 2012).